Renin-Angiotensin and Endothelin Systems in Patients Post-Takotsubo Cardiomyopathy

Hilal Khan, Amelia Rudd, David T Gamble, Alice M Mezincescu, Lesley Cheyne, Graham Horgan, Neeraj Dhaun, David E Newby, Dana K Dawson, Hilal Khan, Amelia Rudd, David T Gamble, Alice M Mezincescu, Lesley Cheyne, Graham Horgan, Neeraj Dhaun, David E Newby, Dana K Dawson

Abstract

Background We investigate if renin-angiotensin and endothelin-1 response pathways follow the same pattern of recovery as left ventricular ejection fraction in patients with takotsubo cardiomyopathy. Methods and Results Ninety patients with takotsubo cardiomyopathy (n=30 in each of "acute," "convalescent" [3-5 months] and "recovered" [>1 year] groups) who were on minimal or no medication and were free of any significant cardiac/metabolic comorbidities, and 30 controls were studied. Serum concentrations of renin, angiotensin-converting enzyme, angiotensin II, big endothelin-1, endothelin-1 were measured using commercially available ELISA, and B-type natriuretic peptide was measured using an immunoassay. Mean left ventricular ejection fraction was <40% during the acute phase in all groups, but recovered to 63% in convalescent and 64% in the recovered groups, respectively. Serum renin concentrations remain persistently elevated after a episode of takotsubo cardiomyopathy (P=0.03 versus controls). Angiotensin converting enzyme levels are significantly depressed during the acute phase compared with convalescent (P=0.004), recovered takotsubo cardiomyopathy (P=0.02) or controls (P=0.03). Angiotensin II is increased in patients with takotsubo cardiomyopathy (P<0.001 versus controls) remaining persistently elevated in the chronically recovered group alone (P=0.03 versus controls). Big endothelin-1 levels are unchanged, but endothelin-1 is significantly lower after takotsubo cardiomyopathy compared with controls (P=0.03). Conclusions Despite "normalization" of the left ventricular ejection fraction, there is long-term maladaptive activation of renin-angiotensin system in patients with takotsubo cardiomyopathy. Registration URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02897739, NCT02989454.

Keywords: angiotensin; cardiomyopathy; endothelin; renin; takotsubo.

Figures

Figure Figure.. Neurohumoral, endothelin and natriuretic peptide…
Figure Figure.. Neurohumoral, endothelin and natriuretic peptide axes in takotsubo cardiomyopathy compared with matched controls.
Serum concentrations of renin (A), angiotensin‐converting enzyme (B), angiotensin II (C), big endothelin‐1 (D), endothelin‐1 (E) and B‐type natriuretic peptide (F) in acute (n=30), convalescent (n=30) and chronically recovered (n=30) patients with takotsubo cardiomyopathy and matched controls (n=30). Data presented as median, 25th and 75th centiles, and maximum and minimum (whiskers) with superimposed individual data points.

References

    1. Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako‐tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55:333–341. doi: 10.1016/j.jacc.2009.08.057
    1. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–938. doi: 10.1056/NEJMoa1406761
    1. Redfors B, Jha S, Thorleifsson S, Jernberg T, Angerås O, Frobert O, Petursson P, Tornvall P, Sarno G, Ekenbäck C, et al. Short‐ and long‐term clinical outcomes for patients with takotsubo syndrome and patients with myocardial infarction: a report from the Swedish coronary angiography and angioplasty registry. J Am Heart Assoc. 2021;10:e017290. doi: 10.1161/JAHA.119.017290
    1. Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, Broadhurst P, Newby DE, Henning A, Dawson DK. Persistent long‐term structural, functional, and metabolic changes after stress‐induced (takotsubo) cardiomyopathy. Circulation. 2018;137:1039–1048. doi: 10.1161/CIRCULATIONAHA.117.031841
    1. Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L, Taddei C, Gabutti A, Poletti R, Giannoni A, et al. Sympathetic and renin‐angiotensin‐aldosterone system activation in heart failure with preserved, mid‐range and reduced ejection fraction. Int J Cardiol. 2019;296:91–97. doi: 10.1016/j.ijcard.2019.08.040
    1. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S. Counter‐regulatory renin–angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17:116–129. doi: 10.1038/s41569-019-0244-8
    1. George J, Mackle G, Manoharan A, Khan F, Struthers AD. High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: a prospective case‐control study. Int J Cardiol. 2014;172:e116–e118. doi: 10.1016/j.ijcard.2013.12.119
    1. McFarlane SI, Winer N, Sowers JR. Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med. 2003;163:2696–2704. doi: 10.1001/archinte.163.22.2696
    1. Jugdutt BI. Apoptosis after reperfused myocardial infarction: role of angiotensin II. Experimental and clinical cardiology. 2004;9:219–228.
    1. Schwarz K, Ahearn TS, Srinivasan J, Neil CJ, Rudd A, Jagpal B, Frenneaux MP, Pislaru C, Horowitz JD, Dawson DK. Alterations in cardiac deformation, timing of contraction and relaxation and early myocardial fibrosis accompany the apparent recovery of acute stress‐induced (takotsubo) cardiomyopathy: an end to the concept of transience. Journal Am Soc Echo. 2017;30:745–755. doi: 10.1016/j.echo.2017.03.016
    1. Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, Celermajer DS, Claggett B, Cleland JGF, Cutlip DE, et al. Latent pulmonary vascular disease may Alter the response to therapeutic atrial shunt device in heart failure. Circulation. 2022;145:1592–1604. doi: 10.1161/CIRCULATIONAHA.122.059486
    1. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin‐1 and big endothelin‐1 in acute myocardial infarction. Lancet. 1989;2:53–54. doi: 10.1016/S0140-6736(89)90303-6
    1. Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Widera C, Franke J, Fijalkowski M, Nowak R, Fijalkowska M, Volkmann I, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 2014;35:999–1006. doi: 10.1093/eurheartj/eht392
    1. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin‐1 or its C‐terminal fragment induced by systemic administration of the endothelin antagonist TAK‐044. Br J Pharmacol. 1996;119:311–314. doi: 10.1111/j.1476-5381.1996.tb15987.x
    1. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin‐1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol. 2007;293:F1433–F1438. doi: 10.1152/ajprenal.00101.2007

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren